


## Life Sciences

2016: Recognized both globally and nationally for its leading life sciences practice, WilmerHale has more than four decades of experience representing biotechnology, pharmaceutical and medical device companies at all stages of growth, as well as venture capitalists and investment banks. We have represented life sciences clients in venture financings, public offerings, mergers and acquisitions, and licensing agreements and collaborations; protected their innovations through patent prosecution and portfolio development; defended their interests in enterprise-critical patent litigation; and navigated regulatory issues vital to their success. The following is a selection of our recent life sciences transactions.



# Counsel of Choice to Life Sciences Innovators

SERVING INDUSTRY LEADERS IN BIOTECHNOLOGY, PHARMACEUTICALS, MEDICAL DEVICES AND BEYOND



### Mergers and Acquisitions/Strategic Alliances and Collaborations



\$510,000,000 (including contingent payments) July 2015



Acquisition by Integra LifeSciences \$312,000,000 July 2015



Sale of global portfolio of hemostasis Mallinckrodt \$410,000,000

(including contingent payments)

February 2016

## Thermo Fisher

Acquisition of Alfa Aesar research chemicals business of Johnson Matthey

£256,000,000 September 2015



Collaboration with Sanofi for the development and commercialization of sotagliflozin



Cancer immunotherapy collaboration with Juno Therapeutics



Microbiome pharmaceutical licensing advice



Hepatitis C collaboration with Janssen Pharmaceuticals

JANUS

Collaboration with Roche for the development of a TLR inhibitor

#### **Venture Capital Financings**



CORVIA MEDICAL









\$40,000,000 Late Stage January 2016

### **Apellis**

\$47,000,000 Fourth Round December 2015



\$217,000,000 First Round May 2015



\$31,500,000 Late Stage June 2015



\$90,000,000 Second Round December 2015



\$40,000,000 Fourth Round June 2015

### Initial Public Offerings



Initial Public and Follow-on Offerings of Common Stock \$344,879,500

Counsel to Issuer February 2015 and December 2015



Initial Public Offering of

American Depositary Shares representing Ordinary Shares \$191,250,000 Counsel to Underwriters

May 2015

// catabasis

Initial Public Offering of

\$69,000,000

Counsel to Issuer

June 2015



\$108,560,000



Counsel to Issuer

March 2015

Initial Public Offering of Initial Public Offering of American Depositary Share representing Ordinary Shares \$39,278,250

Counsel to Issuer February 2016



BIOTIE Initial Public Offering of American Depositary Sha

representing Shares \$64,400,000 Counsel to Underwriters

June 2015



\$106,087,500 Counsel to Issuer September 2015

#### Follow-on Offerings



CONFORMIS

Initial Public Offering of Common Stock

\$155,250,000

Counsel to Issuer

July 2015

Public Offering of Common Stock \$86,250,000 Counsel to Issuer February 2015



Public Offerings of Common Stock \$569,718,750 Counsel to Issuer February 2015 and April 2015



Bellerophon

Initial Public Offering of Common Stock

\$60,000,000

Counsel to Issuer

February 2015

Public Offering of Common Stock \$149,988,750 Counsel to Underwriters July 2015



Public Offering of Common Stock \$141,450,000 Counsel to Issuer February 2015

Ocular .

Public Offering of Common Stock

\$101,200,000

Counsel to Issuer

June 2015



Public Offering of Common Stock \$173,075,000 Counsel to Issuer March 2015



Rule 144A Placement of 3.00% Convertible Senior Notes \$150,000,000 Counsel to Issuer

August 2015



Public Offerings of Common Stock \$149,000,000 Counsel to Issuer

January 2015 and December 2015



Public Offerings of Common Stock \$262,500,000 Counsel to Issuer March 2015 and January 2016









16\_0216 KW 4/16 3000

WilmerHale recognizes its corporate responsibility to environmental stewardship.

Connect with us in 💆 🔊







wilmerhale.com